UMN Pharma Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Yokohama Japan (2004)
Status: Acquired by Shionogi (2019)

Organization Overview

First Clinical Trial
2009
NCT00980447
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

inactivated influenza vaccine (6 trials)

tivantinib (2 trials)

Drugs in Phase 2 Trials (2)

asp7373 (1 trial)

influenza vaccine, recombinant hemagglutinin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 3)

Influenza in Birds (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4